> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Changes in ViiV Triumeq, Dovato Labels
- URL: https://www.fdaweb.com/changes-in-viiv-triumeq-dovato-labels/
- Published: 2021-03-02T12:00:00.000Z
- Updated: 2026-09-14T16:49:02.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5148778

FDA has approved revisions to the labeling for ViiV’s Triumeq (abacavir/dolutegravir/lamivudine) and Dovato (dolutegravir/lamivudine) to include dosing in patients with creatinine clearance between 30 and 49 mL per min. An agency [notice](https://content.govdelivery.com/accounts/USFDA/bulletins/2c49e4b?ref=fdaweb.com) says that drug interaction information for Triumeq and riociguat also was included in the label.